NeoGenomics Stock Analysis, Valuation (NASDAQ:NEO)
Investors can watch the Amigobulls NeoGenomics stock analysis video here. Our NEO analysis video highlights revenue and profit trends along with other important metrics such as valuation to find what makes the stock attractive.
Note: Amigobulls stock rating is our opinion based on the historical performance of the company's fundamentals. It is not indicative of the future performance of the stock.
NeoGenomics, Inc. Stock Rating 2.7/5
Amigobulls NEO stock analysis takes into account various financial ratios like relative valuation, NeoGenomics revenue, growth and return on equity based on latest quarter 2018 Q2 financial statements. We also check NeoGenomics dividend performance. We compare NeoGenomics valuation with its sector peers to gauge relative attractiveness of NEO stock. NeoGenomics stock rating is our opinion about the business fundamentals of the company.
Should you buy NEO stock?
- The lower PS ratio 3.9 for NEO stock versus Medical sector average of 6.2 is a positive for the company.
Should you sell NEO stock?
- NeoGenomics registered an average TTM Net loss of -1%.
- Trading at a PE ratio of 179.3, NEO stock is overvalued in comparison to sector average multiple of 24.5.
- NeoGenomics has a negative return on equity of -1.5. This indicates that the firm is inefficient at generating profits.
NeoGenomics Related Company Stock Videos
Amigobulls NeoGenomics stock analysis helps in evaluating the financial statements of a company to arrive at a conclusion about the fair value of NEO stock. The fundamentals of a company are vital to identify long-term investment opportunities.
Among the financials of the company, NeoGenomics revenue growth along with the profit or net income give a clear picture of the financial health. Technical analysis comes in handy to check whether the market sentiment is in line with the fundamental picture of the company.